Investigation of metronidazole use during pregnancy and adverse birth outcomes

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 9, 2012, Pages 4800-4805

  Koss, Catherine A ^a,b,f   Baras, Dana C ^c,g   Lane, Sandra D ^d,e   Aubry, Richard ^d,e   Marcus, Michele ^c   Markowitz, Lauri E ^a   Koumans, Emilia H ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c EMORY UNIVERSITY   (United States)

^d State University of New York Upstate Medical University: College of Medicine   (United States)

^e SYRACUSE UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METRONIDAZOLE;

ADULT; ARTICLE; COHORT ANALYSIS; CONGENITAL HEART MALFORMATION; CONGENITAL HYDROCEPHALUS; CONGENITAL MALFORMATION; DRUG SAFETY; EAR NOSE THROAT DISEASE; ELECTRONIC MEDICAL RECORD; FEMALE; FETUS OUTCOME; FIRST TRIMESTER PREGNANCY; GASTROINTESTINAL MALFORMATION; GASTROSCHISIS; HUMAN; HYDRONEPHROSIS; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; NERVOUS SYSTEM MALFORMATION; OUTCOME ASSESSMENT; POLYDACTYLY; PREGNANCY; PREMATURE LABOR; PRIORITY JOURNAL; RHABDOMYOMA; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY; TREATMENT INDICATION; TRICHOMONIASIS; UNITED STATES; VAGINITIS;

ABNORMALITIES, DRUG-INDUCED; ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; COHORT STUDIES; FEMALE; FUNGI; HUMANS; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; MATERNAL EXPOSURE; METRONIDAZOLE; MULTIVARIATE ANALYSIS; MYCOSES; NEW YORK; PREGNANCY; PREGNANCY TRIMESTERS; PREMATURE BIRTH; PRENATAL EXPOSURE DELAYED EFFECTS;

EID: 84865426580     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06477-11     Document Type: Article

References (26)

1. Andrews WW, et al. 2003. Randomized clinical trial of metronidazole plus erythromycin to prevent spontaneous preterm delivery in fetal fibronectin-positive women. National Institute of Child Health & Human Development Maternal-Fetal Medicine Units Network. Obstet. Gynecol. 101:847-55. (Pubitemid 36561243)
2. Beard CM, Noller KL, O'Fallon WM, Kurland LT, Dockerty MB. 1979. Lack of evidence for cancer due to use of metronidazole. N. Engl. J. Med. 301:519-522. (Pubitemid 9258259)
3. Burtin P, Taddio A, Ariburnu O, Einarson TR, Koren G. 1995. Safety of metronidazole in pregnancy: a meta-analysis. Am. J. Obstet. Gynecol. 172:525-529.
4. Callahan DB, Weinberg M, Gunn RA. 2003. Bacterial vaginosis in pregnancy: diagnosis and treatment practices of physicians in San Diego, California, 1999. Sex Transm. Dis. 30:645-649. (Pubitemid 36959569)
5. Cantu JM, Garcia-Cruz D. 1982. Midline facial defect as a teratogenic effect of metronidazole. Birth Defects Orig. Artic. Ser. 18:85-88. (Pubitemid 13206434)
6. Carey JC, et al. 2000. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N. Engl. J. Med. 342:534-540.
7. Caro-Paton T, et al. 1997. Is metronidazole teratogenic? A meta-analysis. Br. J. Clin. Pharmacol. 44:179-182. (Pubitemid 27327073)
8. Centers for Disease Control and Prevention. 2010. Guidelines for treatment of sexually transmitted diseases.MMWRMorb. Mortal. Wkly. Rep. 47:8-10. http://www.cdc.gov/std/treatment/2010/default.htm.
9. Committee on Infectious Diseases AAP. 2006. Red Book: 2006 Report of the Committee on Infectious Diseases, 27th ed. American Academy of Pediatrics, EIk Grove Village, IL.
10. Cotch MF, et al. 1997. Trichomonas vaginalis associated with low birth weight and preterm delivery. The Vaginal Infections and Prematurity Study Group. Sex Transm. Dis. 24:353-360. (Pubitemid 27306585)
11. Cunningham FE, Kraus DM, Brubaker L, Fischer JH. 1994. Pharmacokinetics of intravaginal metronidazole gel. J. Clin. Pharmacol. 34:1060-1065. (Pubitemid 24362583)
12. Czeizel AE, Rockenbauer M. 1998. A population based case-control teratologic study of oral metronidazole treatment during pregnancy. Br. J. Obstet. Gynaecol. 105:322-327. (Pubitemid 28123583)
13. Diav-Citrin O, Shechtman S, Gotteiner T, Arnon J, Ornoy A. 2001. Pregnancy outcome after gestational exposure to metronidazole: a prospective controlled cohort study. Teratology 63:186-192. (Pubitemid 32417247)
14. Dobias L, Cerna M, Rossner P, Sram R. 1994. Genotoxicity and carcinogenicity of metronidazole. Mutat. Res. 317:177-194.
15. Greenberg F. 1985. Possible metronidazole teratogenicity and clefting. Am. J. Med. Genet. 22:825.
16. Hauth JC, Goldenberg RL, Andrews WW, DuBard MB, Copper RL. 1995. Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis. N. Engl. J. Med. 333:1732-1736. (Pubitemid 26007124)
17. Kigozi GG, et al. 2003. Treatment of Trichomonas in pregnancy and adverse outcomes of pregnancy: a subanalysis of a randomized trial in Rakai, Uganda. Am. J. Obstet. Gynecol. 189:1398-1400. (Pubitemid 37542180)
18. Klebanoff MA, et al. 2001. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N. Engl. J. Med. 345:487-493. (Pubitemid 32758500)
19. Koumans EH, et al. 2011. Evaluation of Syracuse Healthy Start's program for abnormal flora screening, treatment, and rescreening among pregnant women, Syracuse, New York, 2000-2002. Matern. Child Health J. 15:1020-1028.
20. Leitich H, et al. 2003. Bacterial vaginosis as a risk factor for preterm delivery: a meta-analysis. Am. J. Obstet. Gynecol. 189:139-147. (Pubitemid 36886539)
21. McGregor JA, Hager WD, Gibbs RS, Schmidt L, Schulkin J. 1998. Assessment of office-based care of sexually transmitted diseases and vaginitis and antibiotic decision-making by obstetrician-gynecologists. Infect. Dis. Obstet. Gynecol. 6:247-251. (Pubitemid 29066602)
22. Odendaal HJ, Popov I, Schoeman J, Smith M, Grove D. 2002. Preterm labour - is bacterial vaginosis involved? S. Afr. Med. J. 92:231-234. (Pubitemid 34567767)
23. Piper JM, Mitchel EF, Ray WA. 1993. Prenatal use of metronidazole and birth defects: no association. Obstet. Gynecol. 82:348-352. (Pubitemid 23251351)
24. Rosa FW, Baum C, Shaw M. 1987. Pregnancy outcomes after first-trimester vaginitis drug therapy. Obstet. Gynecol. 69:751-755. (Pubitemid 17057835)
25. Rustia M, Shubik P. 1979. Experimental induction of hepatomas, mammary tumors, and other tumors with metronidazole in noninbred Sas: MRC(WI)BR rats. J. Natl. Cancer Inst. 63:863-868. (Pubitemid 10225018)
26. Sorensen HT, et al. 1999. Safety of metronidazole during pregnancy: a cohort study of risk of congenital abnormalities, preterm delivery and low birth weight in 124 women. J. Antimicrob. Chemother. 44(6):854-856.